Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic human adipose-derived mesenchymal progenitor cells
- Development stage
- Unknown
- Lead developer
- AbelZeta, Inc.
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-articular (injection Into Joint, E.g. For Osteoarthritis)[4], Intravenous, Intrathecal (injection Into Spinal Canal, E.g. For Spinal Cord Injury)[1], Subcutaneous (less Common, Dependent On Indication)
01
Overview
Allogeneic human adipose-derived mesenchymal progenitor cells are multipotent stromal cells isolated from the adipose tissue of human donors other than the recipient. These cells are expanded and formulated for therapeutic use, primarily leveraging their ability to modulate immune responses, promote tissue regeneration, and secrete trophic and anti-inflammatory factors. Their mechanism of action includes the release of bioactive molecules that induce local repair processes, control inflammation, regulate immune activity, foster angiogenesis, and potentially enable neuroregeneration and wound healing. These cells are used as an advanced cell therapy product, notably in regenerative medicine and immunomodulation. The product AlloJoin (brand) is under advanced clinical trials for knee osteoarthritis, reflecting a key use case, with ongoing study of efficacy and safety[4][5][2][3].
- Brand names
- AlloJoin
- Other names
- allogenic adipose-derived mesenchymal progenitor cellsallogeneic adipose-derived mesenchymal stem cellsallogenic AD-MSCsallogeneic adipose tissue-derived mesenchymal stromal cellsadipose-derived mesenchymal stem cells (when referring specifically to allogeneic human source and progenitor population)AD-MSCs (when referring specifically to allogeneic human source and progenitor population)
Beyond the preview
Go deeper on allogeneic human adipose-derived mesenchymal progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic human adipose-derived mesenchymal progenitor cells.